Thèses

Etude de l'evolution sous polychimiothérapie de l'etat neurologique des malades hanseniens nouvellement dépistes : résultats à 3 ans

Auteurs-es

DIOP Madoky Magatte

Synopsis

     

##plugins.themes.clarte.stats.title##

##plugins.themes.clarte.metrics.views##
29
##plugins.themes.clarte.stats.downloads##
3

##plugins.themes.clarte.cites.title##

Références

  1. - BECX-BLEUMINK M., BERTHED. MANNEIJE W.T.
  2. The managment of nerve damage in the leprosy control services.
  3. Lep. Rev., 1990, 61,1-11.
  4. - BLOOM B.R., GODAL T.
  5. Selective primary health care : strategies for control of disease in the developping world. V. Leprosy.
  6. Review of Infectious Diseases, 1983, 5., 765-780.
  7. - BODDINGUS J.
  8. Ultrastructure of begining and progressive nerve involvement in leprosy patient.
  9. XIe Congres International de Leprologie, Mexico, 1978, Abst. 271-276.
  10. - BODDINGUS J.
  11. Mechanisms of peripheral nerve damage in leprosy. Electron and light microscope studies throughout the spectrum.
  12. Quad. Coop. Sanit., 1982, 1; 65-85.
  13. - BOILLOT F.
  14. Aspects actuels de la neuropathie hansenienne.
  15. Th. Doct. Med., 1985, Grenoble.
  16. - BOURREL P.
  17. Strategie et tactique en chirurgie de la lepre.
  18. Acta Lepr. 1984, 2, 55-63.
  19. -BROWNEG.
  20. Corticosteroias in leprosy a guid to their systemic use.
  21. Lepr. Rev., 1964, 35, 157-163.
  22. - BRYCESON A., PFALTZGRAFF R.E.
  23. Leprosy, 2eme ed.
  24. P. 72-76, Churchill Livingstone, Edinburgh, 1979.
  25. - CHAUSSINAND R.
  26. La lepre, 2eme ed. 1955.
  27. Expansion Scientifique Frarn;aise, Paris.
  28. - COLSTON M. J. et al.
  29. Molecular biology of the mycobacteria.
  30. Lepr. Rev., 1989, 60, 89-93.
  31. - DANIELSEN D.C., BOECK C.W.
  32. Our spedalsked-Udgivet after foranstalting af den kongelige Norske Reggeri Department for det
  33. lndre, 1847, 1 Vol. et atlas Trykt hos. C. Grondehl - Christiana, Ed. Princeps Bergen.
  34. Edition Frangaise : traite de la Spedalsked ou Elephantiasis des Grecs, 1848, J.-B, Baillere,
  35. Paris.
  36. - DATSUR D.K., ANTIA N.H., DIVEKAR S.C.
  37. The facial nerve in leprosy. Pathology, pathogenesis, electromyography and 'clinical correlation.
  38. Int. J. Lepr., 1966,34,118-138.
  39. - DESIKAN K.V.
  40. Viability of M leprae outside the human body.
  41. Leprosy Review, 1977, 48, 231-235.
  42. - FAGET G.H. POGGE R.C., JOHANSEN F.A., DINAN J.F., PREDJEAN B.M., ECCLESC.G.
  43. The promin treatment of leprosy.
  44. Public Health Reports, 1943, 58, 1729-1741.
  45. - FAGET G.H., POGGE R.C., JOHANSEN F.A., FITE G.L., PREDJEAN B.M., GEMARF.
  46. Present status of promin treatment of leprosy.
  47. Int. J. Lepr., 1946, 14, 30-36.
  48. - FROMM E., WITTMAN J.
  49. Derivate des P-nitrophenols. ,
  50. Berichte der Deutsche Chemischen Gesellschaft, 1908, 41, 2264-2273.
  51. - GAYLORD H. BRENNANP.J.
  52. Leprosy and leprosy bacillus : recent developments in characterization of antigens and immunology of the disease.
  53. Ann. Rev. Mmicrobiol., 1987, 41, 645-675.
  54. - GELBER R.H.
  55. Activity of minocyline in M leprae infected mice.
  56. J. Inf.Dis., 1987, 186, 236-239.
  57. - GILBODY J.S.
  58. Impact of multidrug therapy on the treatmen and control leprosy.
  59. international journal of leprosy, 1991, 59, 458-478.
  60. - GODAL T. MYRVANG B., STANFORD J.L. SAMUEL D.R.
  61. Recent advances in the immunology of leprosy with special references to new approaches in immuno-prophylaxis.
  62. Bull. Inst. Pasteur, 1974, 72, 273-310.
  63. - GRAUWIN M.Y, MANE I. CARTEL J.L.
  64. Pseudo-epitheliomatous hyperplasia in trophic ulcers in leprosy patients; A 28 cases study.
  65. Lepr. Rev., 1996, 67, 203-207.
  66. - GROSSET J.H., GUELPA-LAURAS C.C., PERANI E.G., BEOLETTO C.
  67. Activity of ofloxacin against M. leprae in the mouse.
  68. Int. J: Lepr. 1988, 56, 259-264.

Téléchargements

##catalog.published##

juillet 4, 2023

Langue

Anglais

Séries

Renseignements à propos de cette monographie

##plugins.themes.clarte.press.citeBook##

APA Magatte, D. M. (2023). Etude de l'evolution sous polychimiothérapie de l'etat neurologique des malades hanseniens nouvellement dépistes : résultats à 3 ans. CODESRIA. https://doi.org/10.57054/codesria.pub.1591

##plugins.themes.clarte.press.shareBook##